Findings

What do systematic reviews say?

5 questions · 6 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 50%Low 3 · 50%Moderate 0 · 0%High 0 · 0%

Methotrexate + infliximab vs infliximab

Failure to enter remission at 14 weeks or 24 weeks (Feagan 2014) · adult patients with refractory Crohn's disease

Methotrexate + infliximab showed no clear difference in failure to enter remission at 14 weeks or 24 weeks (Feagan 2014) compared with infliximab alone (low certainty).

2 findings from 1 review

Methotrexate for induction of remission in refractory Crohn's disease 2014 · Cochrane Headline outcomes only
RR 1.07 [0.57, 2.03]
1 study · 126 participants
Low
Methotrexate for induction of remission in refractory Crohn's disease 2014 · Cochrane Headline outcomes only
RR 0.73 [0.31, 1.69]
1 study · 19 participants
Very low

Methotrexate + infliximab vs infliximab

Adverse events (Schröder 2006) · adult patients with refractory Crohn's disease

It is very uncertain whether methotrexate + infliximab changes adverse events (Schröder 2006) compared with infliximab alone (very low certainty).

1 finding from 1 review

Methotrexate for induction of remission in refractory Crohn's disease 2014 · Cochrane Headline outcomes only
RR 1.02 [0.51, 2.05]
1 study · 19 participants
Very low

Methotrexate + infliximab vs infliximab

Serious adverse events (Schröder 2006) · adult patients with refractory Crohn's disease

It is very uncertain whether methotrexate + infliximab changes serious adverse events (Schröder 2006) compared with infliximab alone (very low certainty).

1 finding from 1 review

Methotrexate for induction of remission in refractory Crohn's disease 2014 · Cochrane Headline outcomes only
RR 0.25 [0.01, 5.45]
1 study · 19 participants
Very low

Methotrexate + infliximab vs infliximab

Withdrawals due to adverse events · adult patients with refractory Crohn's disease

Methotrexate + infliximab showed no clear difference in withdrawals due to adverse event (Feagan 2014) compared with infliximab alone (low certainty).

1 finding from 1 review

Methotrexate for induction of remission in refractory Crohn's disease 2014 · Cochrane Headline outcomes only
RR 2 [0.19, 21.5]
1 study · 126 participants
Low

Methotrexate + infliximab vs Infliximab +/‐ placebo

Maintenance of clinical remission · maintenance of remission in Crohn's disease

Methotrexate + infliximab showed no clear difference in proportion of patients maintaining remission compared with infliximab +/‐ placebo (low certainty).

1 finding from 1 review

Methotrexate for maintenance of remission in Crohn's disease 2014 · Cochrane Headline outcomes only
RR 1.02 [0.76, 1.38]
2 studies · 145 participants
Low